🔗 Share this article

Given that the US proceeds with unprecedented revisions to its vaccine recommendations, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by casting doubt on coronavirus shots throughout the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Public health authorities were set to announce radical revisions to the childhood immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with many the world with little proof for benefit. The announcement has been pushed back until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is listed to speak at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more in line with Denmark, a society with universal health coverage and a citizenry about the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – typically the domain of Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent background in drug development, oversight or administrative roles, which has been customary for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She has no expertise in industry regulation.”

Previous directors of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who headed CBER have had.”

This division has an vast range of responsibilities at the agency, Woodcock pointed out.

“Everybody just focuses on the novel medication approvals, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars program, OTC medication office and more, and each of these must be managed,” Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a substantial administrative component to the position, which oversees more than 5,000 staff members. “It’s a huge administrative position, if you do it right,” Woodcock concluded.

Agency Reaction and Contentious Programs

In response to concerns about Høeg’s credentials and whether this selection signifies greater collaboration among agency officials on vaccines, a spokesperson responded that the “inquiries are based on flawed presumptions”.

“This background is consistent with the duties of her job,” the representative stated, pointing to the period Dr. Høeg spent guiding the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious rapid drug-approval program that reportedly worried her former heads. “By what process are these therapies being chosen for this expedited pathway? Who makes the decisions?” Howard said. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of all drugs, aside from shots.”

Established Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if problematic, past, Howard said. She released a analysis using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the new government featured altering regulations for new vaccines and halting “non-essential” vaccines, she stated following the vote on a online show. At the agency, Høeg has allegedly proposed excluding teenage boys from receiving COVID-19 vaccines.

“She’s an thorough dogmatist who begins with her conclusions and reverse-engineers to retrofit the evidence in a highly disingenuous, dishonest manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|